

Fact Sheet

About:

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. Biocon Biologics, a subsidiary of Biocon Ltd, is uniquely positioned as a fully integrated 'pure play' biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions. It has a platform of 28 biosimilar molecules across diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology and inflammatory diseases. The Company has five of its biosimilars commercialized in the developed markets like U.S., EU, Canada, Japan and Australia. It aspires to benefit 5 million patient lives with its biosimilars and attain a revenue milestone of USD1 billion in FY22.

A Credible Biopharma Enterprise:


- 7 Biologics taken from '**Lab to Market**': 2 Novels & 5 Biosimilars
- ~**120** Countries where our Products are available
- **25+** cGMP Approvals from International Regulatory Agencies*
- Ranked among **Top 10 Global Biotech Employers** by Science magazine
- **Key Brands:** INSUGEN® (rh-insulin), Basalog One® (prefilled Glargine pen), CANMAb™ (Trastuzumab), KRABEVA® (Bevacizumab), BIOMAb-EGFR® (Nimotuzumab) and ALZUMAb™ (Itolizumab)

*As of 31 March 2020

Vision


To enhance
global
healthcare
through
innovative
and
affordable
biopharma
products for
patients,
partners and
healthcare
systems
across the
globe.

Business Revenue Contribution#




#includes inter-segment revenue

Geographic Distribution



Talent Profile



Biocon at a Glance :

Biocon is leveraging its affordable innovation model to reduce disparities in access to safe, high-quality medicines, as well as, address the gaps in scientific research to find innovative solutions to impact a billion lives.

Generics Business: Ensuring access through quality, affordability, reliability

Biosimilars Business: Expanding access through innovative, inclusive healthcare solutions

Research Services Business: Partnering to deliver innovative scientific solutions

Novel Biologics Business: Pushing scientific boundaries to deliver impactful innovations

Branded Formulations Business: Offering patients high quality, differentiated therapies



Revenue ₹ **65,286** Million



Profit for the year*
₹ **7,482** Million



EBITDA Margin - **27** %



R&D Spend (Gross)
₹ **5,271** Million



Employees (Total) - **12,000+**



EPS ₹ **6.3**

*includes exceptional items
All figures are as of March 31, 2020

Growth Verticals: Aligned with Shifting Paradigms

BIOSIMILARS



SMALL MOLECULES

Differentiated APIs &
Generic Formulations

NOVEL BIOLOGICS



BRANDED FORMULATIONS

Finished Dosage
Business in India
& Overseas

**GROWTH
VERTICALS**

RESEARCH SERVICES

Syngene



Manufacturing Locations

Bangalore | Malaysia | Hyderabad | Visakhapatnam



For more information contact:

Seema Ahuja

Sr. VP & Global Head of Communications and Corporate Brand

T: +91-80-2808-2222

Email: seema.ahuja@biocon.com